BGNE - BeiGene Ltd - ADR
IEX Last Trade
191.6
-6.900 -3.601%
Share volume: 293,387
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$198.50
-6.90
-3.48%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-08 | 2022-11-09 | 2023-02-27 | 2023-05-04 | 2023-08-02 | 2023-11-09 | 2024-02-26 | 2024-05-08 | |
| Assets | |||||||||
| Total Assets | 7.378 B | 6.726 B | 6.379 B | 5.957 B | 5.729 B | 5.525 B | 5.805 B | 5.668 B | |
| Current Assets | 6.346 B | 5.749 B | 5.207 B | 4.704 B | 4.401 B | 4.054 B | 4.203 B | 3.908 B | |
| Inventories | 262.210 M | 290.911 M | 282.346 M | 296.995 M | 321.333 M | 316.929 M | 416.122 M | 447.345 M | |
| Other Current Assets | 189.974 M | 188.494 M | 193.776 M | 243.640 M | 218.184 M | 197.750 M | 207.268 M | 188.478 M | |
| Short Term Investments | 189.974 M | 188.494 M | 193.776 M | 243.640 M | 218.184 M | 197.750 M | 207.268 M | 188.478 M | |
| Total Receivables | 189.668 M | 200.442 M | 195.945 M | 330.823 M | 336.148 M | 352.990 M | 394.151 M | 467.112 M | |
| Current Cash | 5.704 B | 5.069 B | 4.535 B | 3.833 B | 3.516 B | 3.174 B | 3.174 B | 2.793 B | |
| Total Non-current Assets | 1.032 B | 976.845 M | 1.172 B | 1.252 B | 1.327 B | 1.471 B | 1.602 B | 1.760 B | |
| Property Plant Equipment | 633.100 M | 681.914 M | 845.946 M | 925.404 M | 1.032 B | 1.178 B | 1.324 B | 1.418 B | |
| Other Assets | 43.259 M | 44.364 M | 78.525 M | 75.310 M | 51.833 M | 49.611 M | 33.007 M | 52.785 M | |
| Intangible Assets | 43.325 M | 40.849 M | 40.616 M | 39.735 M | 46.895 M | 53.657 M | 57.138 M | 55.171 M | |
| Goodwill | 109.000 K | 109.000 K | 109.000 K | 109.000 K | 109.000 K | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 7.378 B | 6.726 B | 6.379 B | 5.957 B | 5.729 B | 5.525 B | 5.805 B | 5.668 B | |
| Total liabilities | 2.076 B | 2.071 B | 1.996 B | 1.799 B | 1.930 B | 1.762 B | 2.268 B | 2.307 B | |
| Total current liabilities | 1.398 B | 1.411 B | 1.469 B | 1.255 B | 1.405 B | 1.283 B | 1.810 B | 1.882 B | |
| Accounts Payable | 234.355 M | 252.071 M | 294.781 M | 241.360 M | 266.975 M | 341.857 M | 315.111 M | 356.575 M | |
| Other liabilities | 435.387 M | 399.320 M | 267.746 M | 290.016 M | 276.169 M | 234.025 M | 221.472 M | 192.445 M | |
| Current long term debt | 380.729 M | 441.275 M | 328.969 M | 281.808 M | 421.052 M | 328.560 M | 688.366 M | 826.965 M | |
| Long term debt | 185.207 M | 208.058 M | 209.148 M | 206.298 M | 207.426 M | 202.491 M | 197.618 M | 199.027 M | |
| Other liabilities | 435.387 M | 399.320 M | 267.746 M | 290.016 M | 276.169 M | 234.025 M | 221.472 M | 192.445 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 5.303 B | 4.655 B | 4.383 B | 4.157 B | 3.799 B | 3.763 B | 3.537 B | 3.360 B | |
| Common stock | 102.805 M | 103.485 M | 103.780 M | 104.167 M | 104.633 M | 104.670 M | 104.079 M | 104.273 M | |
| Retained earnings | -5.972 B | -6.635 B | -7.080 B | -7.429 B | -7.810 B | -7.594 B | -7.962 B | -8.213 B |